Delving into the Latest Updates on Cyclopentolate Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(±)-cyclopentolate, 1-hydroxy-α-phenylcyclopentaneacetic acid 2-(dimethylamino)ethyl ester, 2-(dimethylamino)ethyl 1-hydroxy-α-phenylcyclopentaneacetate

+ [16]

Target

mAChRs

Action

antagonists

Mechanism

mAChRs antagonists(Muscarinic acetylcholine receptor antagonists)

Therapeutic Areas

Nervous System DiseasesEye Diseases

Active Indication

Eye DiseasesCycloplegiaMydriasis

Inactive Indication-

Originator Organization

Santen Pharmaceutical Co., Ltd.

Active Organization

Santen Pharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

Japan (23 Sep 1971),

Eye Diseases

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC17H26ClNO3

InChIKeyRHKZVMUBMXGOLL-UHFFFAOYSA-N

CAS Registry5870-29-1

The primary outcome of this study is to compare cyclopentolate 1% and tropicamide 1% for cycloplegic refractions in pediatric populations with esotropia. This will be a prospective double-blinded randomized clinical trial (RCT), multi-center, with randomized sequencing of cycloplegic agent; each patient received one agent at one visit, and the other agent in the next visit (2 different visits ≥ 1 week apart) within 3 months.

Start Date01 Sep 2023

Sponsor / Collaborator

The Islamic Hospital

[+2]

100 Clinical Results associated with Cyclopentolate Hydrochloride

Login to view more data

100 Translational Medicine associated with Cyclopentolate Hydrochloride

Login to view more data

100 Patents (Medical) associated with Cyclopentolate Hydrochloride

Login to view more data

703

Literatures (Medical) associated with Cyclopentolate Hydrochloride

03 Mar 2025·Cureus Journal of Medical Science

A Case of Pediatric Myasthenia Revealed by Marked Eyelid Ptosis After Using Cyclopentolate Eye Drops

Article

Author: Komatsu, Kaori ; Yoshikawa, Tomoko ; Kiuchi, Yoshiaki

Pediatric myasthenia gravis (PMG), while uncommon, poses significant diagnostic challenges due to its potential impact on development and its often subtle initial symptoms, such as ptosis and diplopia. This case report details an unusual presentation of PMG in a three-year-old female, initially diagnosed with a chalazion, highlighting the complexity of diagnosing this autoimmune neuromuscular disorder in children. Despite treatment for the assumed chalazion, the child's ptosis persisted, and disparities in visual acuity between her eyes became evident. The turning point in her diagnosis came during a routine ophthalmologic assessment using cyclopentolate hydrochloride, which exacerbated her ptosis, prompting further neuromuscular investigation. This led to the detection of acetylcholine receptor antibodies and a suspected diagnosis of PMG after a repetitive nerve stimulation test. This case underscores the critical role of detailed clinical observation and the consideration of neuromuscular etiologies in children presenting with ocular symptoms. It also emphasizes the importance of integrating the observations of family members and caregivers into clinical assessments. Oftentimes, subtle symptoms noted by those close to the patient can provide crucial clues in diagnosing complex conditions like PMG. Early detection is paramount to prevent complications such as amblyopia and to initiate timely interventions, as demonstrated by the subsequent implementation of an eye patch to preserve visual function in the affected eye of the patient. This report contributes to the growing literature on the variable presentations of PMG and underlines the necessity for vigilance and a comprehensive approach in pediatric ophthalmologic evaluations to ensure that significant underlying conditions are not overlooked.

01 Mar 2025·OPTOMETRY AND VISION SCIENCE

Comparative efficacy of tropicamide 1% and cyclopentolate 1% for cycloplegic refraction: A systematic review and meta-analysis of randomized controlled trials

Review

Author: Bist, Jeewanand ; Kandel, Sandeep ; Paudel, Nabin ; Marasini, Sanajay

BACKGROUND:

Cyclopentolate 1% is considered the drug of choice for effective cycloplegic refraction in clinical population, although tropicamide 1% is also reported to have similar effects with better tolerability.

OBJECTIVES:

The objective of this meta-analysis was to evaluate the efficacies of tropicamide 1% and cyclopentolate 1% for cycloplegic refraction.

DATA SOURCES:

MEDLINE, Embase, Scopus, and Cochrane Central Register of Controlled Trials were systematically searched for articles published until March 20, 2024.

STUDY ELIGIBILITY CRITERIA, PARTICIPANTS, AND INTERVENTIONS:

Randomized controlled trials that compared tropicamide 1% with cyclopentolate 1% in terms of differences in spherical equivalent refractive errors were included. The meta-analysis included only nonstrabismic participants with no restriction to age.

STUDY APPRAISAL AND SYNTHESIS METHOD:

The included studies were appraised using the Cochrane Risk of Bias Tool-2. The meta-analysis was conducted using the random-effects model with restricted maximum likelihood estimation method.

RESULTS:

Of 17 full-text reviews from 2555 identified studies, 4 randomized controlled trials were included in quantitative synthesis. The meta-analysis included 171 eyes of 171 participants (age range, 4 months to 50 years), in each group, with all types of refractive errors. The results showed no statistically significant differences in mean spherical equivalent refractive error values between the two groups (mean difference, −0.05; standard error, 0.16; p=0.774). There was no heterogeneity observed between the studies (I2 = 0.00%, p=0.93). The outcome did not change when only children were included in the meta-analysis (age range, 4 months to 16 years; mean difference, −0.14; standard error, 0.21; p=0.51). In the risk-of-bias assessment, generally all studies were judged to have low risk of bias, but only one was judged to have low risk of bias across all seven domains.

CONCLUSIONS:

Tropicamide 1% and cyclopentolate 1% showed similar efficacies for cycloplegic refraction in nonstrabismic children and adults. Considering patient tolerability and drug safety, it may be practical to use tropicamide 1% in routine cycloplegic refractions.

01 Jan 2025·OPHTHALMIC AND PHYSIOLOGICAL OPTICS

Impact of proxymetacaine on the dynamics of cyclopentolate in White 6‐ to 7‐year‐olds

Article

Author: Doyle, Megan ; Harrington, Síofra ; O'Dwyer, Veronica

Abstract:

Purpose:

This study compared the efficacy of cyclopentolate hydrochloride at 10‐, 20‐ and 30‐min post‐instillation in White 6‐ to 7‐year‐olds, with and without prior instillation of proxymetacaine hydrochloride. The primary aim was to determine if accurate autorefraction values can be obtained sooner than the current standard of 30‐min post‐cycloplegia. The secondary aim was to investigate whether proxymetacaine hydrochloride enhances the efficiency of cyclopentolate.

Methods:

Participants were 112 White 6‐ to 7‐year‐olds from the Child Eye Health Study. The right eye received 0.5% proxymetacaine hydrochloride and 1.0% cyclopentolate hydrochloride, and the left eye received only 1.0% cyclopentolate hydrochloride. Non‐cycloplegic and cycloplegic refractive error (at 0, 10, 20 and 30 min) was measured using a binocular, open‐field autorefractometer. Data were analysed through paired t‐tests, concordance analysis, linear regression, equivalence testing and Bland–Altman analysis, using the 95% limits of agreement.

Results:

Mean spherical equivalent refraction (SER) (SD) in the right eye at 0‐, 10‐, 20‐ and 30‐min post‐instillation was 0.62 (1.45) D, 1.52 (1.80) D, 1.64 (1.81) D and 1.72 (1.80) D, respectively. Mean left eye SER (SD) were 0.68 (1.24) D, 1.42 (1.66) D, 1.56 (1.66) D and 1.68 (1.72) D, respectively. Bland–Altman analysis showed a high level of agreement, and equivalence testing confirmed that there was no clinically significant difference in SER at 20 and 30 min in both eyes (within ±0.50 D), with mean differences of 0.08 (0.23) D in the right eye and 0.13 (0.30) D in the left eye (p = 0.21). However, SER at 10 and 30 min were equivalent in the right eye only.

Conclusions:

Accurate autorefraction values can be obtained 20‐min post‐instillation of 1.0% cyclopentolate in white children aged 6–7 years, potentially reducing clinical testing times. Proxymetacaine pre‐instillation allows for reliable measurements as early as 10‐min post‐instillation of cyclopentolate. Further research is needed to validate these findings in non‐White populations and to determine the safe discharge time post‐proxymetacaine instillation.

1

News (Medical) associated with Cyclopentolate Hydrochloride

12 Aug 2024

·www.prnewswire.com

OcuMension acquires rights to Alcon eye drops in exchange for a 16.7% equity stake, signaling the commencement of comprehensive strategic relationship

SHANGHAI, Aug. 12, 2024 /PRNewswire/ -- On August 13th 2024, Ocumension Therapeutics (" OcuMension") announced an agreement with Alcon Inc. (" Alcon", and collectively with OcuMension, the " Parties") where OcuMension will acquire or secure commercialization rights in China to a portfolio of Alcon dry eye treatments and procedural drops, including several commercially available products and one development-stage product. The scope of the agreement will also cover areas of R&D, manufacturing and commercialization in China. In connection with the transfer of these rights, OcuMension will issue 139,161,120 shares to Alcon, accounting for 16.71% of the total share capital (post-issuance). Consequently, Alcon becomes one of the largest shareholders of OcuMension. Under the terms of the arrangement, each company has granted the other company a right of first negotiation over future products. OcuMension, as a leading Chinese ophthalmic pharmaceutical platform company, focuses on integrating comprehensive capabilities across the entire lifecycle of ophthalmic drug development—from research and development to commercialization. OcuMension possesses a portfolio of 25 pharmaceutical assets. Alcon, the global leader in eye care, offers a broad portfolio of products to enhance sight and improve lives for patients in more than 140 countries. Under this arrangement, OcuMension will acquire outright, Tears Natural® Forte, Bion Tears, Alcaine®, Fluorescite, and Cyclogyl, in the Chinese market and the commercialization rights in China to Systane® Ultra and AR-15512, a novel topical drug candidate for dry eye. Under the terms of this agreement, OcuMension will manufacture those products acquired outright for China after a transition period. OcuMension will also develop, manufacture and commercialize AR-15512 in China. The addition of these seven mature products and AR-15512 to OcuMension's portfolio is expected to further enhance OcuMension's leadership in the ophthalmology field in the China market. Through the acquisition of these products, OcuMension expects to be capable of providing more comprehensive and advanced treatment solutions, further meeting patient needs and expanding market share. The Parties expect that the framework of this agreement will allow both Parties to further promote technological advancements and innovations in the field of ophthalmology. Ophthalmic diseases are internationally recognized as one of the highly focused medical sub-sectors, with innovative treatment solutions for ophthalmology still awaiting development. Based on this, OcuMension will continue to focus on bringing safer, more efficient, and cutting-edge treatment solutions to global ophthalmic patients, meeting the growing medical needs of patients. About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, Alcon offers the broadest portfolio of products to enhance sight and improve people's lives. Alcon's Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Alcon's more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at . About OcuMension OcuMension is a China-based ophthalmic pharmaceutical platform company dedicated to identifying, developing and commercializing first- or best-in-class ophthalmic therapies. OcuMension's vision is to provide a world-class pharmaceutical total solution to address significant unmet ophthalmic medical needs in China. Since its inception, OcuMension has focused on building a platform integrating specialized capabilities in each major functionality involved in an ophthalmic drug's development cycle, from research and development, manufacturing to commercialization. OcuMension believes its platform positions it well to achieve leadership in China ophthalmology, with a first-mover advantage over future competitors. Advisors Morrison Foerster acted as legal advisor to OcuMension in this transaction. Lazard acted as financial advisor to Alcon and Gibson Dunn as its legal advisor. SOURCE OcuMension

AcquisitionLicense out/in

100 Deals associated with Cyclopentolate Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01002	Cyclopentolate Hydrochloride	S01FA04	DB00979

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Eye Diseases	Japan	Santen Pharmaceutical Co., Ltd.	23 Sep 1971
Cycloplegia	United States	-	-
Mydriasis	United States	-	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02909140 (CTgov)	Not Applicable	Cataract	3	Topical phenylephrine 2.5%+Topical cyclopentolate 1%+Intracameral Lidocaine 1% (Topical Mydriasis)	meilynnejh(pbkvxkdgmp) = acvrjdfqnh vixowauxak (vjyymsibmi, wmtbmvprgg - fvuudmhogw) View more	-	10 Sep 2019
				Intracameral 0.2- 0.3ml of epinephrine 1:10,000+Intracameral Lidocaine 1% (Intracameral Mydriasis)	omqgvismxl = yjmzpwpgnr olxcbwuays (hwhmbtwddi, fonvvwswkd - mnokugeodb) View more
Pubmed \| Curr Eye Res	Not Applicable	Retinopathy of Prematurity	25	Cyclopentolate	qptdtnvvre(dwvreizixc) = Preterm infants undergoing Retinopathy of Prematurity Eye Exams (ROPEE) may experience adverse events, possibly from systemic absorption of cyclopentolate. qwngxihsiv (svemkgmbxi ) View more	-	01 Dec 2016
				Cyclopentolate
ARVO2015	Not Applicable	-	8	Cyclopentolate 1%	lphdqerdph(rmdlhsnlck) = rltobyatxx fyhzfrqqhz (ittghpjyrs ) View more	-	01 Jun 2015
Pubmed \| Eur J Ophthalmol	Not Applicable	Retinopathy of Prematurity	1,246	Phenylephrine 2.5% with Cyclopentolate 0.5%	hpjtalgdjy(geowkvqkjs) = kinvpxjpvz tvgnkcrmis (yihnccckmf )	-	01 May 2015
ARVO2013	Not Applicable	Myopia	28	cyclopentolate (Myopic children)	raxwrvqwvq(mfzcnwakum) = vrsqpsrzne malikbxjqw (tauhqvdong ) View more	-	01 Jun 2013
AAAAI2011	Not Applicable	-	67	Phenylephrine	cbvwrshhlm(azqvcjtpkr) = tfxxjxsipr jmxahyaunp (rmckzqsbbo ) View more	Positive	01 Feb 2011
				Atropine	cbvwrshhlm(azqvcjtpkr) = iwjqjwisgc jmxahyaunp (rmckzqsbbo ) View more
Multi-Ethnic Pediatric Eye Disease Study (ARVO2008)	Not Applicable	Refractive Errors	24	Cyclopentolate	ucmmmedbda(gxvqzwbvap) = yylnfwmqsw siuxjhivad (ymxijltcuu, 0.85) View more	Positive	01 May 2008
				Atropine	ucmmmedbda(gxvqzwbvap) = crazhfwliy siuxjhivad (ymxijltcuu, 0.85)